内向整流钾通道6．2基因E23K多态性与2型糖尿病表型及格列齐特降糖疗效的关系

Association of E23K polymorphism of inwardly rectifying K^+channel 6.2 gene with the phenotype of type 2 diabetes and glucose-lowering effect of gliclazide

研究内向整流钾通道6.2(Kir6.2)基因E23K多态性对2型糖尿病临床表型及格列齐特降糖疗效的影响。结果提示K/K纯合子患者的血肌酐水平高于其它基因型患者(P<0.01),E23K多态性不影响格列齐特的降糖疗效。

The influences of E23K polymorphism of inwardly rectifying K^＋ channel 6.2 （Kir6.2） gene on the clinical phenotype of type 2 diabetes and glucose-lowering effect of gliclazide were investigated. The result showed that E23K polymorphism did not influence glucose-lowering effect of gliclazide, but serum creatinine level of patients with K/K genotype was higher than those of E/E and E/K genotypes （P 〈 0.01 ）.